Albireo to Host Virtual Investor Commercial Day 2021
January 07 2021 - 8:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver
disease company developing novel bile acid modulators, today
announced that it will host a virtual Commercial Day for investors
on February 11 from 11:30-1:00pm EST.
Presentations will include an overview of the long-term
corporate strategy, the global market opportunity in rare pediatric
and adult liver disease, and the global commercialization strategy
and launch readiness plans for odevixibat in progressive familial
intrahepatic cholestasis (PFIC), an ultra-rare pediatric
cholestatic liver disease.
The event will be hosted by Ron Cooper, President and Chief
Executive Officer and members of Albireo leadership.
Commercial Day Call Details for Thursday, February 11
from 11:30-1:00pm ESTDomestic:
1-877-407-0792International:
1-201-689-8263Conference ID:
13714756Participant Webcast Link:
http://public.viavid.com/index.php?id=142919
The virtual event will also be accessible from the Albireo Media
and Investors page ir.albireopharma.com.
About AlbireoAlbireo Pharma is a
clinical-stage biopharmaceutical company focused on the development
of novel bile acid modulators to treat rare pediatric and adult
liver diseases, and other adult liver diseases and disorders.
Albireo’s lead product candidate, odevixibat, is being developed to
treat rare pediatric cholestatic liver diseases with Phase 3
pivotal trials in PFIC, Alagille syndrome and biliary atresia. The
Company completed IND-enabling studies for new preclinical
candidate A3907 this year and plans to advance development in adult
liver disease. Albireo was spun out from AstraZeneca in 2008
and is headquartered in Boston, Massachusetts, with its
key operating subsidiary in Gothenburg, Sweden.
The Boston Business Journal named Albireo one of the 2020
Best Places to Work in Massachusetts for the second
consecutive year. For more information on Albireo, please
visit www.albireopharma.com.
Media & Investor contacts:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.com Hans Vitzthum,
LifeSci Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Sep 2023 to Sep 2024